
Benzinga Pro data, Arbutus Biopharma (NASDAQ:ABUS) reported Q4 sales of $3.21 million. Earnings fell to a loss of $21.32 million, resulting in a 11.29% decrease from last quarter. Arbutus Biopharma collected $3.34 million in revenue during Q3, but reported earnings showed a $19.16 million loss.